Clinical trials: Adjuvant Treatment
Breast Cancer Female, Hormone Receptor Positive Tumor
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis.
- Trial name
- LALEAST (NCT03917082)
- Testing
- Tamoxifen Citrate
- Where
- Canada
- Volunteers
- 290 people
- Sponsor
- British Columbia Cancer Agency
Digestive System Malignant Solid Tumors
Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors
This is an open-lable, single-arm, single-dose escalation and multiple-dose extention clinical study of cell therapy designed to observe and evaluate the tolerance, the pharmacokinetic characteristics, the safety and the efficacy…
- Trial name
- NCT05730361
- Testing
- ScTIL injection, ScTIL injection and B lymphocytes adjuvant
- Volunteers
- 48 people
- Sponsor
- Peking University
Colorectal Neoplasms, Anesthesia
Effects of Anesthetic Techniques on Time to Start of Adjuvant Chemotherapy Following Surgery for Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer in the world with a high postoperative mortality (2 - 6%) as well as a low 5-year survival (40%).
- Conditions
- Colorectal Neoplasms, Anesthesia, Drug Therapy, Surgery
- Trial name
- ENCORE (NCT04493905)
- Where
- Sweden
- Volunteers
- 5,500 people
- Sponsor
- European Society of Anaesthesiology
Colon Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
The purpose of this study is to evaluate the efficacy, safety, and tolerability of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of oral mucositis in subjects with stage 2B and 3…
- Trial name
- NCT00393822
- Testing
- palifermin
- Volunteers
- 100 people
- Sponsor
- Amgen
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and…
- Trial name
- NCT03767582
- Testing
- Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma, Adjuvant Therapy
TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
This is An Open, Single Arm, Multicenter, Exploratory Phase II study, to evaluate the efficacy and safety of TQB2450 Plus anlotinib as adjuvant therapy in hepatocellular carcinoma(HCC) patients at high risk of recurrence after…
- Trial name
- ALTER-H006 (NCT05111366)
- Testing
- TQB2450 injection, Anlotinib hydrochloride capsules
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Xianhai Mao
Malignant Melanoma
A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)
This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after definitive surgical resection including complete…
- Trial name
- NCT01636960
- Testing
- PegIFN alfa-2b
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
This is a randomized study comparing the use of Anastrozole before and continuing during radiotherapy for breast cancer compared to the use of anastrozole after irradiation.
- Trial name
- NCT00126360
- Testing
- Timing of Anastrozole in respect to radiotherapy
- Where
- 4 sites in Australia
- Volunteers
- 100 people
- Sponsor
- St George Hospital, Australia
Seasonal Allergic Rhinoconjunctivitis
Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis
The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen allergic patients.
- Trial name
- NCT01111279
- Testing
- gpASIT+TM, gpAST+TM/adjuvant
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- BioTech Tools S.A.
Biliary Tract Cancer
A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
This is a Phase Ib, open-label,single-arm, clinical study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1 (PD-L1)…
- Trial name
- NCT04608786
- Testing
- ZKAB001 5mg/kg, Capecitabine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lee's Pharmaceutical Limited
Hepatocellular Carcinoma
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
This is a multi-center, single arm study to evaluate the efficacy and safety of donafenib in combination with envafolimab treatment in patients with high risk of recurrent hepatocellular carcinoma after radical surgery.
- Trial name
- NCT06498622
- Testing
- Donafenib + Envafolimab
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Anhui Provincial Hospital
Head and Neck Cancer
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002702
- Testing
- aldesleukin, adjuvant therapy, conventional surgery
- Where
- 7 sites in Italy
- Volunteers
- 260 people
- Sponsor
- European Institute of Oncology
Prostate Cancer
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00016913
- Testing
- carboplatin, estramustine, paclitaxel
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
3D Specimen Maps for RT Planning
The primary objective of this study is to measure the impact of patient-specific 3D specimen maps on adjuvant radiation treatment volumes and doses to critical organs.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Radiation Therapy
- Trial name
- NCT05743569
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt University Medical Center
Diabete Mellitus, Type 2 Diabetes
Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes
This clinical trial was conducted at the National Diabetes Center for Treatment and Research, Mustansiriyah University, Baghdad (Sept 2024-May 2025).
- Conditions
- Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus, Dyslipidemia in Patients With Diabetes Mellitus
- Trial name
- NCT07172269
- Testing
- Sitagliptin + Metformin, mangosteen supplement, Lifestyle Management
- Where
- Iraq
- Volunteers
- 58 people
- Sponsor
- Mais Qais Hbeeb
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant…
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-3 (NCT04927780)
- Testing
- Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride
- Where
- 21 sites in Netherlands, Sweden
- Volunteers
- 378 people
- Sponsor
- Erasmus Medical Center
Sarcoma, Melanoma
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
Background: Certain types of cancers, including sarcoma and melanoma, have specific antigens (protein molecules) on their surfaces.
- Conditions
- Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies
- Trial name
- NCT01313429
- Testing
- Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
RAINBO MMRd-GREEN is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab for one year is compared to adjuvant pelvic external beam…
- Trial name
- RAINBO-GREEN (NCT05255653)
- Testing
- Pelvic external beam radiotherapy, Chemotherapy, Durvalumab
- Where
- 60 sites in Belgium, Canada and 5 more
- Volunteers
- 316 people
- Sponsor
- Leiden University Medical Center
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation
Early Stage Non-Small Cell Lung Cancer
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT03050554
- Testing
- Avelumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Andrew Sharabi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.